A patented formulation to improve absorption of CBD and other cannabinoids in the body
Harvest One Cannabis Inc. reports that the medical subsidiary of Satipharm Ltd. a wholly owned subsidiary of the company launched the European sale of its newly-modified CBD capsules.
"The first product on the market is Satipharm 10mg CBD Gelpell® capsule that provides the ultimate in bioavailability and quality," says Harvest One, a global cannabis production company developing media and providing products and wellness products to consumers and patients in regulated markets around the world. Currently available online at www.satipharm.com.
Distribution of brick and mortar capsules "will follow with large retailers across the United Kingdom and the European Union, followed by Canadian distribution," the company said in a statement.
Satipharm emphasizes that its technology "improves the absorption of CBD and other cannabinoids in the body through the patented CBD hemp extract formulation contained in seamless Gelpell® gelatin biosphere. in the small intestine, thereby improving the bioavailability and ensuring that patients receive a constant dose of CBD, "he adds.
"We are delighted with the launch of the new Satipharm web site and e-commerce platform," said Captain Cooks, offering consumers across Europe, commented Jonathan Hartshorn, president of the company.
"Launch of Satipharm's patented CBD Gelpell® capsules is an integral part of Harvest One's health and wellness strategy," adds Grant Froese, CEO of Harvest One. "We look forward to launching additional production lines as we improve our health and wellness strategy on regulated markets around the world," says Foese.
Do you want to be in the process of what is happening in the cannabis world? Subscribe to the Cannabis Post newsletter for a weekly insight into the industry, and the content of the postmedia network will be discussed by the payee.